NASDAQ: NKTXNkarta Inc Stock
$6.79+0.29 (+4.46%)
Updated May 31, 2024
NKTX Price
$6.79
Fair Value Price
-$1.17
Market Cap
$478.48M
52 Week Low
$1.28
52 Week High
$16.24
P/E
-2.89x
P/B
1.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$116.20M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.22
Operating Cash Flow
-$94M
Beta
1.59
Next Earnings
Jun 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NKTX Overview
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NKTX ($6.79) is overvalued by 680.83% relative to our estimate of its Fair Value price of -$1.17 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NKTX ($6.79) is not significantly undervalued (680.83%) relative to our estimate of its Fair Value price of -$1.17 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NKTX due diligence checks available for Premium users.
Be the first to know about important NKTX news, forecast changes, insider trades & much more!
NKTX News
Valuation
NKTX fair value
Fair Value of NKTX stock based on Discounted Cash Flow (DCF)
Price
$6.79
Fair Value
-$1.17
Undervalued by
680.83%
NKTX ($6.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NKTX ($6.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NKTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NKTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.89x
Industry
-14.17x
Market
28.44x
NKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
6.04x
NKTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NKTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$29.5M
Profit Margin
0%
NKTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$576.9M
Liabilities
$103.3M
Debt to equity
0.22
NKTX's short-term assets ($442.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NKTX's short-term assets ($442.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.5M
Investing
$21.5M
Financing
$226.3M
NKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NKTX vs Biotech Stocks
Nkarta Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.